title: Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study.
abstract: A total of 168 patients with de novo AML were retreated with chemotherapy at relapse following first CR; 66 patients (39%) achieved a second complete remission (CR). The probability of achieving a second CR was highly dependent on the duration of the first remission. Patients who received no or conventional postremission chemotherapy after second CR had a median remission duration of 7.5 months, and the probability of remaining in remission at 3 years was 24%. Patients with a first CR of more than 12 months had a median second remission duration of 18 months. The probability of a second CCR was 35% at 3 years and 24% at 5 years, whereas none of the patients with a first CR of less than 12 months was in remission at 3 years. Only a poor correlation (p = 0.31) was found when the durations of the first and second CR were compared in patients with a second relapse. Patients with long-lasting remissions and long-term survivors after second CR are characterized by a first CR duration of > 12 months and favorable or normal cytogenetics. The type of salvage treatment seems to be less important for achievement of long-term remission, but it is probably important to administer consolidation chemotherapy after second CR. Other so-far ill-defined factors may be responsible for the suppression of the leukemic clone in patients with long-lasting remissions following chemotherapy for relapse after second CR.
authors.affiliation: Department of Medicine I, University of Vienna, Austria.
authors.forename: F
authors.initials: F
authors.lastname: Thalhammer
authors.forename: K
authors.initials: K
authors.lastname: Geissler
authors.forename: U
authors.initials: U
authors.lastname: Jäger
authors.forename: P A
authors.initials: PA
authors.lastname: Kyrle
authors.forename: I
authors.initials: I
authors.lastname: Pabinger
authors.forename: M
authors.initials: M
authors.lastname: Mitterbauer
authors.forename: H
authors.initials: H
authors.lastname: Gisslinger
authors.forename: P
authors.initials: P
authors.lastname: Knöbl
authors.forename: K
authors.initials: K
authors.lastname: Laczika
authors.forename: B
authors.initials: B
authors.lastname: Schneider
authors.forename: O A
authors.initials: OA
authors.lastname: Haas
authors.forename: K
authors.initials: K
authors.lastname: Lechner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome